Evotec’s Strategic Pivot Gains Traction Amid Investor Scrutiny

Evotec SE is navigating a critical transformation, and recent financial moves and market activity suggest the plan is beginning to resonate. The Hamburg-based drug discovery firm is shifting away from capital-intensive manufacturing toward a more asset-light, high-margin licensing model, a strategy underscored by a significant asset sale and a rigorous cost-cutting program.

The company’s recent presence at major industry conferences, including the AACR Annual Meeting in San Diego and the Life Science Innovation Northwest event in Seattle, served to reassure the market. This visibility signaled that its ongoing restructuring is not coming at the expense of scientific progress or its core platform technologies. In Seattle, the focus was on its biologics subsidiary, highlighting its role in biopharmaceutical manufacturing.

Financially, the cornerstone of this shift was the December 2025 sale of its Just – Evotec Biologics EU1 production facility in Toulouse to Sandoz. The deal netted Evotec an upfront payment of approximately $350 million, with the potential for an additional $300 million in milestone payments in the coming years. Future royalties on up to ten biosimilars could also flow in, targeting a market valued at over $90 billion.

This influx of capital supports the broader “Horizon” transformation plan launched in March 2026. The initiative aims to streamline the company’s structure and redirect resources toward more profitable, IP-driven programs. Management targets annual cost savings of around €75 million by the end of 2027, building on a separate savings goal of over €60 million for 2025.

Should investors sell immediately? Or is it worth buying Evotec?

Operational figures provide a mixed but stabilizing backdrop. For the full year 2025, revenue saw a slight decline to €788 million. However, the final quarter showed resilience with sales of approximately €253 million and an operating result of €58 million. The company continues to operate its first J.POD site in Seattle, which currently hosts over 100 programs with more than 30 partners.

Investors have responded positively to the evolving strategy. The share price has rallied roughly 36% from its March low, currently trading at €5.68. The stock now sits comfortably above its 50-day moving average, with the 200-day line within close reach. A breakout above this level could put the previous high of €8.32 back in sight.

Analyst opinions on the path forward vary widely, reflecting the transitional nature of the current phase. RBC Capital Markets has set an ambitious price target of €10, while Deutsche Bank sees fair value at just €4.50. HC Wainwright recently initiated coverage with a “Buy” rating and a $7.00 price target, citing an undervaluation of Evotec’s platform technologies. The consensus average price target remains above the current trading level, even as experts, on average, still forecast a 2026 loss per share of €0.41.

The immediate focus now turns to execution. The company has labeled 2026 a “transition year,” with the first half expected to bear restructuring costs before improved operational leverage materializes in the second half. The next key test arrives on 6 May 2026, with the release of the Q1 2026 report. Markets will scrutinize whether revenue in the Discovery & Preclinical Development segment remains stable and if the “Horizon” plan is beginning to show tangible cost benefits.